N. Yin

Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).

S. Shumack, G. Chan, H. Valdez, 2022, Journal of the American Academy of Dermatology.

Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis

J. Cappelleri, C. Feeney, M. Dibonaventura, 2022, Advances in Therapy.

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study

M. D. de Bruin‐Weller, H. Valdez, S. Barbarot, 2022, Dermatology and Therapy.

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals

H. Valdez, M. Dowty, M. O’Gorman, 2022, European Journal of Drug Metabolism and Pharmacokinetics.